Prenuvo launches 10-year, 100,000 participant study on whole-body MRI screening

Company aims to ‘pave the way’ for whole-body MRI to become standard of care and available to all.

Whole-body MRI screening company Prenuvo today launched a major new clinical research study at the Hercules Research Center in Boston. This study, the largest of its kind, will follow 100,000 participants over a decade to assess the diagnostic and clinical outcomes of whole-body MRI screening in the general population and identify new disease biomarkers.

The study of Prenuvo’s technology, which is designed to detect hundreds of health conditions seamlessly, aims to demonstrate the efficacy of the approach in a proactive healthcare model, compared with traditional reactive healthcare methods.

“There is an unmet health-system need to enable, detection of early-stage disease processes before they become irreversible chronic or progressive clinical disease-states, when gentler, less invasive, and less costly interventions (or even sometimes risk factor management) are more likely to have a chance at preventing or reversing the course of the disease,” said Dr Yosef Chodakiewitz, the radiologist leading the Hercules study.

Prenuvo is on a mission to shift healthcare from reactive “sick-care” to a proactive model, and now operates screening clinics in Vancouver, Silicon Valley, Dallas, Boca Raton, Minneapolis, Los Angeles, New York City and Chicago. Scanning an entire body in under an hour, the company claims its scans capture over one billion data points and produce ten times more clinical-grade images than traditional MRIs.

The results of the study could have implications for human healthspan and longevity. Catching diseases early, perhaps even before symptoms even arise, are when lifestyle changes can still make a big difference.

Prenuvo founders Andrew Lacy and Dr Raj Attariwala.

“This is key for longevity because it provides people with knowledge and data about their health, information that’s critical to improving outcomes and potentially increasing healthy years,” Prenuvo’s CEO Andrew Lacy told us. “By investing in the largest clinical study of the effectiveness of clinical-grade MRI screening ever conducted, Prenuvo’s goal is to pave the way for such technology to be standard of care and available to all. Doing so will lead to longevity improvements that are measured in years for all, and produce a leaner health system focused on proactive rather than reactive medicine.”

The clinical study will target a diverse participant base, emphasizing health-equity to address disparities in healthcare access. To ensure inclusivity, the study will subsidize participation costs for individuals from under-represented demographics, particularly those facing healthcare inequity and financial challenges. At least 10% and up to 50% of participants will meet health equity qualifications, with subsidies covering 50-100% of their participation costs. These criteria include being a SNAP (Supplemental Nutrition Assistance Program) participation, ensuring a broad representation of historically medically under-served groups, including BIPOC (Black, Indigenous, and people of color) individuals.

Prenuvo’s is keen to address these disparities, claiming that under-representation in clinical research can undermine the goals of such studies. By enrolling a diverse cohort, the study aims to provide a comprehensive understanding of health and disease across different populations.

For more information on the study, eligibility criteria and financial assistance options, interested individuals can visit the study’s website.